adenylosuccinic acid

Phase 1Small molecule

CCure ADSSL1

adenylosuccinic acid is one of 31 small molecule programs targeting Myopathy. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MyopathyActive, not recruiting

MyopathyPhase 1

Active, not recruiting

Competition

Competitive Landscape

40 competitors in Myopathy

#DrugCompanyPhaseTrials

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

2 2

Viagra

VViatris Specialty LLC

Approved

1 3

Zocor

OOrganon and Co

Approved

1 4

Acetadote

AArbor Pharmaceuticals, Inc.

Approved

—5

Mesnex

BBaxter Healthcare Corporation

Approved

—6

Cytoxan

BBaxter Healthcare Corporation

Statins

1 8

Dantrium

AAultman Health Foundation

Phase 3

1 9

Skyclarys

Biogen

Phase 2

1 10

Zilbrysq

UCB

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Not yet recruiting

Myopathy

NCT07412821

Clinical

Trials by Indication[1]

Myopathy1 trial

A Phase 1b Study of Adenylosuccinic Acid (ASA-001) for Adenylosuccinate Synthase 1 (ADSS1) Deficient Myopathy.

Not yet recruiting·CCure ADSSL1·Phase 1·NCT07412821·2 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for adenylosuccinic acid. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — adenylosuccinic acid compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for adenylosuccinic acid. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cure ADSSL1 company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: CCure ADSSL1

adenylosuccinic acid

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Myopathy1 trial

References

Drug Info

Quick Facts

Related News